Skip Navigation

European Journal of Heart Failure 1999 1(2):133-137; doi:10.1016/S1388-9842(99)00025-2
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by O'Callaghan, P. A.
Right arrow Articles by Camm, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Callaghan, P. A.
Right arrow Articles by Camm, A. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1999 European Society of Cardiology

Treatment of arrhythmias in heart failure

Peter A. O'Callaghan* and A. John Camm

Department of Cardiological Sciences, St George's Hospital Medical School Cranmer Terrace, London SW17 ORE, UK

* Corresponding author. Tel.: +44-181-725-5916; fax: +44-181-767-7141 e-mail: pocallag@sghms.ac.uk

Key Words: Arrhythmia • Antiarrhythmia agents • Heart failure • Death, sudden • Defibrillation

Accepted April 7, 1999

The first 150 words of the full text of this article appear below.


   1. Introduction
 
The last decade has seen major advances in the treatment of congestive heart failure and left ventricular systolic dysfunction. Nevertheless, despite conventional medical therapy including diuretics, digoxin, and angiotensin converting enzyme (ACE) inhibitors, the mortality rate associated with this condition remains unacceptably high, in the range of 5–15% annually in mild heart failure and increasing to 20–50% annually in patients with severe heart failure [1]. Angiotensin-converting enzyme (ACE) inhibitors reduce total mortality in patients with cardiac failure but in most trials do not reduce the frequency of ventricular arrhythmias or sudden cardiac death [2,3]. Sudden cardiac death is responsible for approximately half of all cardiac deaths in patients with heart failure. Sudden and unexpected death accounts for the majority of deaths in mild heart failure; in contrast death due to progressive pump failure accounts for the majority of deaths in severe heart failure (. . . [Full Text of this Article]


   2. Secondary prevention of life-threatening ventricular tacyhyarrhythmias
 
2.1. The decline of pharmacologic therapy
2.2. The rise of device therapy

   3. Primary prevention of sudden cardiac death
 
3.1. Risk stratification and primary prevention

   4. Conclusion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?